Clinical Trials Sponsored by Suzhou Landing Pharmaceuticals

Total 358 results

Suzhou Landing Pharmaceuticals

Completed

Pharmacoinvasive Therapy With Prourokinase

ST-segment Elevation Myocardial Infarction (STEMI)

China
Suzhou Kintor Pharmaceutical Inc,

Terminated

A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

Covid19

United States, China, Philippines, South Africa, Ukraine
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Suzhou Kintor Pharmaceutical Inc,

Completed

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

Androgenetic Alopecia

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Castrate Resistant Prostate Cancer (mCRPC)

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)

HCC | Metastatic Hepatocellular Carcinoma | Combinations of Drugs; Dependence

Taiwan
Suzhou Kintor Pharmaceutical Inc,

Completed

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

Efficacy and Safety

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Alopecia | Male Pattern Hair Loss

United States
Suzhou Kintor Pharmaceutical Inc,

Terminated

A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

COVID-19

Brazil
Suzhou Kintor Pharmaceutical Inc,

Completed

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Acne Vulgaris | Androgenetic Alopecia

United States
Suzhou Kintor Pharmaceutical Inc,

Active, not recruiting

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

HCC | Hepatocellular Carcinoma

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

Androgenetic Alopecia

United States
Suzhou Kintor Pharmaceutical Inc,
Suzhou Koshine Biomedica, Inc.

Active, not recruiting

Phase III Study of KX-826 With Adult Male Patients With AGA

Androgenetic Alopecia

China
Suzhou Koshine Biomedica, Inc.

Completed

To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

Alopecia

China
3H (Suzhou) Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Solid Tumors With FGFR2 Alterations, Adult

China
3H (Suzhou) Pharmaceuticals Co., Ltd.

Not yet recruiting

A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Solid Tumors With FGFR2 Alterations, Adult

United States
Suzhou Erye Pharmaceutical Co., Ltd.

Recruiting

Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Infections

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Recruiting

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Treatment Side Effects | Treatment

China
Heyu (Suzhou) Pharmaceutical Technology Co., Ltd

Recruiting

Phase I Clinical Study of HY01 in Patients

Sudden Sensorineural Hearing Loss

China
Huashan Hospital
Sumitomo Pharmaceuticals (Suzhou) Co. Ltd

Unknown

WGS-guided Tracking and Infection Control Measures of CRKP

Klebsiella Pneumoniae Infection

China
Inovio Pharmaceuticals
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Infection | COVID-19 Disease

United States, Mexico, Colombia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CStone Pharmaceuticals

Recruiting

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Raymon Pharmaceuticals Company, Ltd.
WuXi Clinical

Active, not recruiting

RMP-A03 Ocular Suspension in Patients With Pterygium

Pterygium

United States
Nanjing Zenshine Pharmaceuticals

Not yet recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of ZX-7101A Tablets to Evaluate the Efficacy and Safety in the Treatment of Uncomplicated Influenza in Adolescents (ZX-7101A-207)

Respiratory Viral Infection

China
Nanjing Zenshine Pharmaceuticals

Not yet recruiting

Substance Balance Study of [14C]ZX-7101A in Healthy Adult Male Subjects in China

Influenza, Human
Nanjing Zenshine Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Pharmacokinetics | Tolerance | Safety Issues | Food Effect

China
Nanjing Zenshine Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects (QTc-ZX-7101A)

Influenza, Human

China
Nanjing Zenshine Pharmaceuticals

Not yet recruiting

A Study to Assess the Effect of Itraconazole Capsules on the Pharmacokinetics of ZX-7101A Tablets in Healthy Adult Subjects in China

Pharmacokinetics

China
Nanjing Zenshine Pharmaceuticals

Recruiting

Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Nanjing Zenshine Pharmaceuticals

Recruiting

A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects (ZX-7101A-208)

Drug Interaction

China
Nanjing Zenshine Pharmaceuticals

Recruiting

Pharmacokinetic Characteristics of Subjects With Hepatic Insufficiency and Healthy Subjects

Influenza, Human

China
Nanjing Zenshine Pharmaceuticals

Recruiting

A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults With Uncomplicated Influenza

Influenza, Human

China
Nanjing Zenshine Pharmaceuticals

Recruiting

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

Non Hodgkin Lymphoma | Peripheral T Cell Lymphoma | CLL/SLL

China
Nanjing Zenshine Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Drug Interaction Study of SY-004 Capsules in Healthy Subjects

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-008 in Healthy Subjects

Diabetes

China
Keythera Pharmaceuticals (Australia) Pty Ltd

Recruiting

A Study of KF-0210 in Advanced Solid Tumors Patients

Gastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the Esophagus

Australia
Jiesi Yingda Pharmaceutical Technology (Suzhou)...

Recruiting

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)

Advanced Non-small Cell Lung Cancer

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Recruiting

SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis

Sepsis

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Food-drug Interaction Study of SY-004 in Healthy Subjects

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

Sepsis

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

Cerebral Apoplexy

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China

Clinical Trials Sponsored by Suzhou Landing Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations